Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179,492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.
Kimball AB, Podda M, Alavi A, Miller M, Shen YK, Li S, Xu Y, Han C, Fakharzadeh S, Yang YW, DePrimo S, Munoz E, Chen Y, Passeron T, Papp K. Kimball AB, et al. Among authors: chen y. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2098-2108. doi: 10.1111/jdv.19252. Epub 2023 Jun 27. J Eur Acad Dermatol Venereol. 2023. PMID: 37317022 Clinical Trial.
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P, Schappin R, Florencia EF, van Heeswijk B, Prens LM, van der Zee HH, Prens EP, van Straalen KR, Horváth B. Dudink K, et al. Among authors: chen y. Br J Dermatol. 2023 Apr 20;188(5):601-609. doi: 10.1093/bjd/ljad010. Br J Dermatol. 2023. PMID: 36811949 Clinical Trial.
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung MWL, Eyerich K. Schäkel K, et al. Among authors: chen y. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2016-2027. doi: 10.1111/jdv.19236. Epub 2023 Jul 18. J Eur Acad Dermatol Venereol. 2023. PMID: 37262309 Clinical Trial.
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.
Blauvelt A, Gordon KB, Langley RG, Branigan PJ, Chen Y, Miller M, Han C, Fakharzadeh S, Muñoz-Elías EJ, Armstrong AW. Blauvelt A, et al. Among authors: chen y. J Invest Dermatol. 2024 Dec;144(12):2816-2819.e2. doi: 10.1016/j.jid.2024.05.020. Epub 2024 Jun 25. J Invest Dermatol. 2024. PMID: 38936766 Free article. No abstract available.
Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.
Blauvelt A, Chen Y, Branigan PJ, Liu X, DePrimo S, Keyes BE, Leung M, Fakharzadeh S, Yang YW, Muñoz-Elías EJ, Krueger JG, Langley RG. Blauvelt A, et al. Among authors: chen y. JID Innov. 2024 Jun 26;4(5):100297. doi: 10.1016/j.xjidi.2024.100297. eCollection 2024 Sep. JID Innov. 2024. PMID: 39224116 Free PMC article.
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut FJH, Kohler K, Chen Y, Sendecki J, Leung MWL, Wegner S, Personke Y, Gomez M, Krüger N, Tabori S, Schäkel K. Eyerich K, et al. Among authors: chen y. JAMA Dermatol. 2024 Sep 1;160(9):953-963. doi: 10.1001/jamadermatol.2024.2463. JAMA Dermatol. 2024. PMID: 39083288 Free PMC article. Clinical Trial.
Drug Development.
Wang P, Sun W, Gong J, Han X, Xu C, Chen Y, Yang Y, Luan H, Li S, Li R, Wen B, Lv S, Wei C. Wang P, et al. Among authors: chen y. Alzheimers Dement. 2024 Dec;20 Suppl 6:e088925. doi: 10.1002/alz.088925. Alzheimers Dement. 2024. PMID: 39782652
Drug Development.
Lundin SK, Hu X, Feng J, Lundin KK, Li L, Chen Y, Schulz PE, Tao C. Lundin SK, et al. Among authors: chen y. Alzheimers Dement. 2024 Dec;20 Suppl 6:e084745. doi: 10.1002/alz.084745. Alzheimers Dement. 2024. PMID: 39782518
179,492 results
You have reached the last available page of results. Please see the User Guide for more information.